Welcome Wondros Family and
Friends! We are beta testing and need
your help improving this product.
Share Feedback
Locations
1 locations
Status
Completed
Study Type
Interventional
Timeframe
Day of admission to day of discharge, estimated 10 days later
Accepts healthy volunteers
No
Age
18 Years +
Gender
All
Placebo Arm
No
Locations
1 locations
Status
Active, not recruiting
Study Type
Interventional
Timeframe
12 Months
Accepts healthy volunteers
No
Age
18 Years - 75 Years
Gender
All
Placebo Arm
No
Locations
1 locations
Status
Recruiting
Study Type
Interventional
Timeframe
Baseline to 12 Weeks
Accepts healthy volunteers
No
Age
45 Years - 70 Years
Gender
Male
Placebo Arm
Yes
Locations
6 locations
Status
Recruiting
Study Type
Interventional
Timeframe
Baseline up to end of treatment
Accepts healthy volunteers
No
Age
18 Years +
Gender
Male
Placebo Arm
No
Locations
1 locations
Status
Withdrawn
Study Type
Interventional
Timeframe
28 days
Accepts healthy volunteers
No
Age
18 Years +
Gender
All
Placebo Arm
Yes
Locations
44 locations
Status
Active, not recruiting
Study Type
Interventional
Timeframe
Extension period through Week 108
Accepts healthy volunteers
No
Age
12 Years +
Gender
All
Placebo Arm
Yes
Locations
1 locations
Status
Completed
Study Type
Interventional
Timeframe
Through study completion, an average 1 year
Accepts healthy volunteers
No
Age
4 Years - 18 Years
Gender
All
Placebo Arm
Yes
Locations
1 locations
Status
Recruiting
Study Type
Interventional
Timeframe
2 weeks
Accepts healthy volunteers
No
Age
18 Years - 75 Years
Gender
All
Placebo Arm
No
Locations
38 locations
Status
Recruiting
Study Type
Interventional
Timeframe
at every single visit up to 60 months
Accepts healthy volunteers
No
Age
18 Years - 70 Years
Gender
All
Placebo Arm
Yes
Locations
1 locations
Status
Active, not recruiting
Study Type
Interventional
Timeframe
Change from Baseline to End of Study (week 12)
Accepts healthy volunteers
No
Age
18 Years - 85 Years
Gender
All
Placebo Arm
Yes
Locations
1 locations
Status
Recruiting
Study Type
Interventional
Timeframe
baseline, 1-month
Accepts healthy volunteers
No
Age
+
Gender
All
Placebo Arm
No
Locations
1 locations
Status
Not yet recruiting
Study Type
Interventional
Timeframe
Up to 3 months post-therapy
Accepts healthy volunteers
No
Age
18 Years - 100 Years
Gender
All
Placebo Arm
No
Locations
1 locations
Status
Recruiting
Study Type
Interventional
Timeframe
24 months
Accepts healthy volunteers
No
Age
11 Years - 15 Years
Gender
All
Placebo Arm
No
Locations
1 locations
Status
Recruiting
Study Type
Observational
Timeframe
Through study completion, an average of 12 months
Accepts healthy volunteers
No
Age
+
Gender
Female
Placebo Arm
No
Locations
1 locations
Status
Completed
Study Type
Interventional
Timeframe
9 weeks
Accepts healthy volunteers
No
Age
18 Years +
Gender
All
Placebo Arm
No
Locations
31 locations
Status
Recruiting
Study Type
Interventional
Timeframe
At Month 3
Accepts healthy volunteers
No
Age
18 Years +
Gender
All
Placebo Arm
No
Locations
1 locations
Status
Active, not recruiting
Study Type
Interventional
Timeframe
8 weeks
Accepts healthy volunteers
No
Age
18 Years - 45 Years
Gender
Female
Placebo Arm
Yes
Locations
14 locations
Status
Recruiting
Study Type
Interventional
Timeframe
up to 24 months
Accepts healthy volunteers
No
Age
18 Years +
Gender
All
Placebo Arm
No
Locations
2 locations
Status
Recruiting
Study Type
Interventional
Timeframe
4 weeks
Accepts healthy volunteers
No
Age
18 Years - 65 Years
Gender
All
Placebo Arm
No
Locations
1 locations
Status
Completed
Study Type
Observational
Timeframe
At day 1 of study participation
Accepts healthy volunteers
No
Age
18 Years +
Gender
All
Placebo Arm
No
Locations
7 locations
Status
Active, not recruiting
Study Type
Interventional
Timeframe
Baseline up to 12 months after last participant enrolled in Cohort
Accepts healthy volunteers
No
Age
18 Years +
Gender
All
Placebo Arm
No
Locations
10 locations
Status
Recruiting
Study Type
Interventional
Timeframe
Until disease progression (up to 4 years)
Accepts healthy volunteers
No
Age
18 Years +
Gender
All
Placebo Arm
No
Locations
2 locations
Status
Recruiting
Study Type
Interventional
Timeframe
comparasion in EMU for 3-14 days period, where patients are hospitalized.
Accepts healthy volunteers
No
Age
18 Years - 75 Years
Gender
All
Placebo Arm
No
Locations
1 locations
Status
Active, not recruiting
Study Type
Observational
Timeframe
11 days
Accepts healthy volunteers
No
Age
18 Years - 65 Years
Gender
All
Placebo Arm
No
Locations
17 locations
Status
Completed
Study Type
Interventional
Timeframe
Up to Day 30
Accepts healthy volunteers
No
Age
12 Months - 15 Months
Gender
All
Placebo Arm
No
Rural Home Hospital: Proof of Concept
This study examines the implications of providing hospital-level care in rural homes.
Sponsored by:
Brigham and Women's Hospital
Trial Location:
University of Utah Health, Salt Lake City, Utah 84132, United States
Estimated trial timing:
February 18, 2021 - May 07, 2021
EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial
This is a pragmatic, 24 month, single-center, randomized, open-label, parallel-group trial comparing an obesity-centric approach with a medically-s...
Sponsored by:
The Cleveland Clinic
Trial Location:
Cleveland Clinic, Cleveland, Ohio 44195, United States
Estimated trial timing:
September 01, 2020 - March 01, 2023
Wild Blueberries and Cardiovascular Health in Middle-aged/Older Men and Postmenopausal Women
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. Aging is the primary risk factor for CVD, in large part due...
Sponsored by:
Colorado State University
Trial Location:
Food and Nutrition Clinical Research Laboratory, Fort Collins, Colorado 80523-1571, United States
Estimated trial timing:
January 01, 2020 - December 31, 2023
Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland
This phase IIa trial investigates the biomarker (plasma levels of PSA) of low-dose apalutamide in patients with prostate cancer confined in the pro...
Sponsored by:
National Cancer Institute (NCI)
Trial Location:
UC San Diego Medical Center - Hillcrest, San Diego, California 92103, United States
Estimated trial timing:
June 01, 2021 - August 31, 2024
Outpatient Use of Ivermectin in COVID-19
Covid 19, a novel coronavirus, causes infection that, while mild to moderate in many people, can lead to severe disease in a significant portion. C...
Sponsored by:
Temple University
Trial Location:
Temple University Hospital, Philadelphia, Pennsylvania 19140, United States
Estimated trial timing:
April 01, 2021 - June 30, 2021
Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
The purpose of this study is to evaluate the duration of response following withdrawal of ruxolitinib cream (Cohort A vehicle group), safety and ma...
Sponsored by:
Incyte Corporation
Trial Location:
Northwestern University, Chicago, Illinois 60611, United States
Estimated trial timing:
September 24, 2020 - November 04, 2022
Probiotics and Antibiotic Associated Diarrhea in Pediatric Complicated Appendicitis
To determine the effectiveness of the use of probiotics in patients with a diagnosis of complicated appendicitis on antibiotic associated diarrhea ...
Sponsored by:
Children's Health
Trial Location:
Children's Health Children's Medical Center, Dallas, Texas 75235, United States
Estimated trial timing:
September 08, 2020 - February 28, 2022
Using Electrical Nerve Stimulation to Control Atrial Fibrillation
The purpose of this study is to examine if sending mild electrical signals just under your skin will improve atrial fibrillation symptoms by contro...
Sponsored by:
Cedars-Sinai Medical Center
Trial Location:
CedarsSinaiMC, Los Angeles, California 90048, United States
Estimated trial timing:
November 24, 2021 - July 01, 2023
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
Phase 3 randomized, double-blind, placebo-controlled, study assessing the efficacy and safety of acalabrutinib plus rituximab,cyclophosphamide, dox...
Sponsored by:
Acerta Pharma BV
Trial Location:
Research Site, Clayton, 3168, Australia
Estimated trial timing:
October 08, 2020 - August 31, 2026
Oral Nutritional Supplement Effect on HDL Function
Evaluate the effects of a proprietary supplement on total HDL, HDL functionality, HDL particle size and HDL particle number (HDL-P)
Sponsored by:
Metagenics, Inc.
Trial Location:
Hypertension Institute, Nashville, Tennessee 37205, United States
Estimated trial timing:
August 18, 2020 - December 30, 2022
Mixed Reality Based System to Manage Phantom Pain Phantom Pain for Patients With Lower Limb Amputation
The primary goals of this pilot research project are a) to design and develop the a mixed reality based system for managing phantom pain and b) to ...
Sponsored by:
Dallas VA Medical Center
Trial Location:
VA North Texas Health Care System, Dallas, Texas 75216, United States
Estimated trial timing:
May 21, 2018 - June 30, 2021
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
This phase II trial investigates how well 177Lu-DOTATATE works in treating patients with breast cancer that is stage IV or has come back (recurrent...
Sponsored by:
OHSU Knight Cancer Institute
Trial Location:
OHSU Knight Cancer Institute, Portland, Oregon 97239, United States
Estimated trial timing:
September 01, 2022 - December 20, 2023
Biomolecular Characteristics of Reminder-Focused Positive-Psychiatry
Objective: Posttraumatic stress disorder (PTSD) is a prevalent neuropsychiatric disorder in children and is associated with increased neurovascular...
Sponsored by:
University of California, Los Angeles
Trial Location:
UCLA, Los Angeles, California 90024, United States
Estimated trial timing:
May 01, 2022 - December 28, 2023
Tumor Grade Determines PD-1/PDL-1 Expression
Endometrial carcinoma is the most common gynecologic cancer in the western world. Two types are usually described. Type I is the endometrioid and i...
Sponsored by:
RWJ Barnabas Health at Jersey City Medical Center
Trial Location:
Jersey city medical center, Jersey City, New Jersey 07302, United States
Estimated trial timing:
August 25, 2020 - September 30, 2021
Testing the Effectiveness of Coping With Cancer in the Kitchen
The study was a two-arm, randomized controlled trial in which cancer survivors were evenly assigned to either receive the 8-week CCK in-person nutr...
Sponsored by:
American Institute for Cancer Research
Trial Location:
Cancer Support Community Los Angeles, Los Angeles, California 90025, United States
Estimated trial timing:
April 30, 2019 - October 08, 2019
A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema
Part A of the study is conducted to select the THR-149 dose level. Part B of the study is conducted to assess the efficacy and safety of the selec...
Sponsored by:
Oxurion
Trial Location:
King's College Hospital NHS Foundation Trust, London, SE5 9RS, United Kingdom
Estimated trial timing:
July 31, 2020 - March 01, 2023
Cannabidiol and Management of Endometriosis Pain
The investigators are looking to conduct a study looking at the effects of cannabidiol (CBD) in patients with endometriosis. It is believed that CB...
Sponsored by:
Milton S. Hershey Medical Center
Trial Location:
Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania 17033, United States
Estimated trial timing:
December 04, 2020 - June 01, 2023
Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Me...
This is an open-label, randomized, multi-site, Phase II, interventional trial designed to evaluate the efficacy, tolerability, and safety of BNT111...
Sponsored by:
BioNTech SE
Trial Location:
Hospital Clinic de Barcelona, Barcelona, 08036, Spain
Estimated trial timing:
May 19, 2021 - June 01, 2025
Effects of Low FODMAP Diet on Leaky Gut
The pathophysiology of Irritable bowel syndrome (IBS) is multifactorial involving complex interplay of altered intestinal permeability, mucosal imm...
Sponsored by:
Beth Israel Deaconess Medical Center
Trial Location:
Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, United States
Estimated trial timing:
May 20, 2019 - December 01, 2021
Detecting SARS-CoV-2 in Tears
Purpose: To determine the presence of SARS-CoV-2 in tears To determine SARS-CoV-2 receptors in tear production system
Sponsored by:
University of Minnesota
Trial Location:
University of Minnesota, Minneapolis, Minnesota 55455, United States
Estimated trial timing:
September 01, 2021 - December 30, 2021
Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib
This study is designed to evaluate the discontinuation/re-treatment of pexidartinib therapy in previously treated participants with tenosynovial gi...
Sponsored by:
Daiichi Sankyo, Inc.
Trial Location:
Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States
Estimated trial timing:
October 20, 2020 - April 18, 2024
Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced So...
This trial will evaluate the safety and efficacy of first time in human engineered T-cell therapies, in participants with advanced tumors.
Sponsored by:
GlaxoSmithKline
Trial Location:
GSK Investigational Site, Toronto, Ontario M5G 2M9, Canada
Estimated trial timing:
December 21, 2020 - February 13, 2024
Evaluation of the 24/7 EEG SubQ System for Ultra Long-Term Recording of Patients With Temporal Lobe Epilepsy
The 24/7 EEG™ SubQ system will be compared to simultaneously recorded video-EEG in the Epilepsy Monitoring Unit (gold standard) and to self-reporte...
Sponsored by:
UNEEG Medical A/S
Trial Location:
Mayo Clinic, Phoenix, Arizona 85054, United States
Estimated trial timing:
April 21, 2021 - August 30, 2023
Development of Validated Bruise Scale in HNV
Subjects will have a mechanically induced bruise photographed over a period of 11 days to record the healing process. Assessors will rate the bruis...
Sponsored by:
Cearna, Inc.
Trial Location:
Artemis Clinical Research, San Diego, California 92109, United States
Estimated trial timing:
September 25, 2020 - April 28, 2021
A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison ...
The purpose of this study is to evaluate the safety and tolerability of three dose levels of ASP3772 in comparison to the active comparator Prevnar...
Sponsored by:
Affinivax, Inc.
Trial Location:
Dermatology Trial Associates, Bryant, Arkansas 72022, United States
Estimated trial timing:
September 22, 2020 - April 06, 2022
Our website uses cookies, as almost all websites do, to help provide you with the best experience we can. You can learn more about all the cookies and the information we collect by reading our Privacy Policy.
